.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,026,274

« Back to Dashboard

Details for Patent: 8,026,274

Title:Use of oxandrolone in the treatment of burns and other wounds
Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
Inventor(s): Fishbein; Don (Westfield, NJ)
Assignee: Savient Pharmaceuticals, Inc. (East Brunswick, NJ)
Filing Date:Mar 12, 2004
Application Number:10/799,197
Claims:1. A method of promoting weight gain after weight loss resulting from post-burn catabolism in a patient in need thereof which comprises administering to the patient 10 mg to 100 mg of oxandrolone per day in conjunction with a protein supplement to achieve a daily protein intake by the patient of approximate 2.0 g/kg/day, for a period of three weeks.

2. A method according to claim 1 wherein the amount of oxandrolone administered is about 80 mg per day.

3. A method according to claim 1 wherein the amount of oxandrolone administered is about 20 mg per day.

4. A method according to claim 1 wherein the amount of oxandrolone administered is about 10 mg per day.

5. A method according to claim 1 wherein the oxandrolone is administered orally.

6. A method according to claim 1 wherein the oxandrolone is administered topically.

7. A method according to claim 1 wherein the oxandrolone is administered by injection.

8. A method according to claim 1 wherein the oxandrolone is in a solid dosage form.

9. A method according to claim 1 wherein the oxandrolone is in a liquid dosage form.

10. A method according to claim 1 wherein the oxandrolone is in a sustained-release formulation.

11. A method according to claim 1 wherein the oxandrolone is 17.alpha.-methyl-17.beta.-hydroxy-2-oxa-5.alpha.-androstan-3-one.

12. A method according to claim 1 wherein the weight gain comprises lean body weight gain.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc